1.94 0.16 (8.99%) | 04-23 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 12.89 | 1-year : | 19.71 |
Resists | First : | 11.04 | Second : | 16.88 |
Pivot price | 3.07 | |||
Supports | First : | 1.6 | Second : | 1.33 |
MAs | MA(5) : | 1.81 | MA(20) : | 5.89 |
MA(100) : | 10.62 | MA(250) : | 14.56 | |
MACD | MACD : | -2.8 | Signal : | -2.7 |
%K %D | K(14,3) : | 1.3 | D(3) : | 0.8 |
RSI | RSI(14): 28.1 | |||
52-week | High : | 37 | Low : | 1.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EFTR ] has closed above bottom band by 42.1%. Bollinger Bands are 87.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 1.99 - 2 | 2 - 2.01 |
Low: | 1.76 - 1.77 | 1.77 - 1.78 |
Close: | 1.92 - 1.94 | 1.94 - 1.96 |
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Tue, 09 Apr 2024
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference - GlobeNewswire
Fri, 05 Apr 2024
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails - Zacks Investment Research
Thu, 04 Apr 2024
Why Is eFFECTOR Therapeutics Stock Plummeting On Thursday? - eFFECTOR Therapeutics (NASDAQ:EFTR) - Benzinga
Thu, 04 Apr 2024
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with ... - GlobeNewswire
Tue, 26 Mar 2024
Effector Therapeutics Inc Down 11.74% To $11.97 After Earnings Miss - InvestorsObserver
Mon, 25 Mar 2024
EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023 - InvestorPlace
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 4 (M) |
Shares Float | 3 (M) |
Held by Insiders | 3.6 (%) |
Held by Institutions | 17.5 (%) |
Shares Short | 345 (K) |
Shares Short P.Month | 222 (K) |
EPS | -16.38 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.95 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -85.3 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -9.15 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -30 (M) |
Levered Free Cash Flow | -18 (M) |
PE Ratio | -0.12 |
PEG Ratio | 0 |
Price to Book value | -1 |
Price to Sales | 0 |
Price to Cash Flow | -0.25 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |